Home
About
Overview
Sharing Data
ORCID
Help
History (8)
Postcards as Topic
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Thomas, Gary
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
See All 8 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010 May 06; 115(18):3796-800.
View in:
PubMed
subject areas
Animals
Blotting, Western
Cell Line, Tumor
Cullin Proteins
Cyclopentanes
DNA Damage
Fluorescent Antibody Technique
fms-Like Tyrosine Kinase 3
Humans
Leukemia, Myeloid, Acute
Mice
NEDD8 Protein
NF-kappa B
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Pyrimidines
Reactive Oxygen Species
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
Signal Transduction
Ubiquitins
Xenograft Model Antitumor Assays
authors with profiles
Michael Joseph O'Dwyer